Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
I don’t need an algorithm to identify a frail, elderly multiple myeloma (MM) patient who may not benefit from toxic chemotherapy while leaving the patient with therapy-induced collateral damage (side effects).
This statistic means that more than half of newly diagnosed MMers are NOT represented in clinical trials.
My conventional myeloma therapies of chemotherapy and radiation left me exhausted with damage to my heart, brain, eyes and nervous system. I was 35 years old at the time…
Please scroll down the page to learn about non-toxic therapies to support heart, brain and especially bone health. We MM survivors, regardless of age, can benefit from non-toxic therapies such as magnesium l threonate.
I am both a long-term MM survivor and MM cancer coach. I have remained in complete remission since April of 1999 by living an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, bone health, etc. therapies. Myeloma is a complicated, difficult cancer for a 35 year old much less a person over the age of 70.
If you have been diagnosed with multiple myeloma and you are over 70 I believe that you would benefit from the evidence-based, integrative and complementary, non-toxic therapies provided in the Multiple Myeloma Cancer Coaching Program.
Scroll down the page to ask a question or make a comment. I will reply to you ASAP.
“About one-third of patients with multiple myeloma are older than 75 years at diagnosis, and at least 30% are frail. This is “both due to disease-related symptoms and (age-related) decline in physical capacity, presence of comorbidities, frailty, polypharmacy, nutritional status, and cognitive impairment…”
The treatment challenge is that regimens “investigated in clinical trials for transplant-ineligible patients have largely been investigated in fit, rather than frail patients, the latter being typically excluded or highly underrepresented therein,” the authors wrote.
Dr Zweegman and colleagues described how to identify frail patients with multiple myeloma and how to tailor treatment thereafter. They noted that over the past decade, the proteasome inhibitors bortezomib, carfilzomib, and ixazomib, as well as the immunomodulatory agents (iMiDs) thalidomide, lenalidomide, and pomalidomide “have significantly improved” patient outcomes.
“However, both in clinical trials and in daily clinical practice, elderly multiple myeloma patients have shown lesser benefit. This is mainly due to less stringent use of proteasome inhibitors and IMiDs, increased toxicity, and subsequent early discontinuation of therapy in elderly,” the authors noted.
When asked whether physicians in general practice either do not treat the elderly, do not add proteasome inhibitors/ImiDs, or whether they use a lower dose of novel agents because older patients included in clinical trials may be fitter than “real-world” patients, Dr Zweegman told Cancer Therapy Advisor, “yes, I do…although with less intensity treatment might well be feasible and should be offered…”
Two algorithms in particular can “easily identify intermediate-fit and frail patients:” the International Myeloma Working Group (IMWG)-frailty index and the Revised Myeloma Comorbidity Index (R-MCI).
In managing frail patients with multiple myeloma, Dr Zweegman noted that colleagues should “consider that the disease also causes frailty, so you might well improve quality of life by treatment…”
I am a long-term cancer survivor and cancer coach. As of 2014, the American Cancer Society reported that there are 14.5 million of us. Most of us cancer survivors are over 50. Because of the long-term and late stage collateral damage done by conventional therapies most, if not all cancer survivors must think about maintaining our brain health.
Magnesium supplementation helps manage brain, heart, and bone health. Lucky for me as I live with chemobrain, chronic A-Fib, and nerve damage (peripheral neuropathy). Sarcasm doesn’t really work in my blog posts…
The study linked and excerpted below cites Magnesium L Threonate supporting increased brain health in memory and learning. I take is Life Extension NeuroMag to supplement with Magnesium L-Threonate because of the study below.
My example anecdotal but my chemobrain continues to improve, my chronic A-Fib inflicted heart continues to do its job (without medication) and I continue to remain cancer-free.
The Consumer lab.com evaluation of magnesium supplements that cites the benefits below requires membership log in–
Lastly, magnesium has been shown to improve bone mineral density.
“Summary: Learning and memory are fundamental brain functions affected by dietary and environmental factors. Here, we show that increasing brain magnesium using a newly developed magnesium compound (magnesium-L-threonate, MgT) leads to the enhancement of learning abilities, working memory, and short- and long-term memory in rats.
The pattern completion ability was also improved in aged rats. MgT-treated rats had higher density of synaptophysin-/synaptobrevin-positive puncta in DG and CA1 subregions of hippocampus that were correlated with memory improvement. Functionally, magnesium increased the number of functional presynaptic release sites, while it reduced their release probability. The resultant synaptic reconfiguration enabled selective enhancement of synaptic transmission for burst inputs. Coupled with concurrent upregulation of NR2B-containing NMDA receptors and its downstream signaling, synaptic plasticity induced by correlated inputs was enhanced. Our findings suggest that an increase in brain magnesium enhances both short-term synaptic facilitation and long-term potentiation and improves learning and memory functions.”